Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Opiant Pharmaceuticals Inc. (OPNT) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 12,750
  • Shares Outstanding, K 2,020
  • Annual Sales, $ 9,900 K
  • Annual Income, $ -7,810 K
  • 36-Month Beta N/A
  • Price/Sales 1.29
  • Price/Book 0.00
  • Price/Earnings ttm 7.36
  • Earnings Per Share ttm 0.85
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.5200 +26.81%
on 01/10/17
7.7000 -9.09%
on 01/17/17
+0.4400 (+6.71%)
since 12/16/16
3-Month
5.0100 +39.72%
on 11/10/16
8.2500 -15.15%
on 10/21/16
-1.2000 (-14.63%)
since 10/17/16
52-Week
5.0100 +39.72%
on 11/10/16
11.7500 -40.43%
on 03/21/16
-1.5995 (-18.60%)
since 01/15/16

Most Recent Stories

More News
Opiant Pharmaceuticals, Inc., Reports Fiscal First Quarter 2017 Financial Results and Provides Corporate Update

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial...

Opiant Pharmaceuticals, Inc. Announces NARCAN(R) Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that it...

Opiant Pharmaceuticals, Inc. Announces Appointment of Thomas T. Thomas to Board of Directors

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the appointment...

Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial...

Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and National Institute on Drug Abuse

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that it has obtained...

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for Narcan(R) Nasal Spray Patent

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced today that its...

Opiant Pharmaceuticals, Inc.'s Partner, Adapt Pharma Limited, Announces NARCAN(R) Nasal Spray Approved by Health Canada

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that NARCAN(R)...

Opiant Pharmaceuticals to Present at the Rodman & Renshaw Conference on September 13 in New York City

Opiant Pharmaceuticals, Inc. ("Opiant") (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, will present at the Rodman...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Support & Resistance

2nd Resistance Point 7.5233
1st Resistance Point 7.1467
Last Price 7.0000
1st Support Level 6.2967
2nd Support Level 5.8233

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.